It may be that, in future studies, individual gliomas will show differential expression of HER2/neu and EGFR and that it will be prudent to both phenotype and functionally test each tumor as a target, in order to choose the best BiAb. The gene discussed is ERBB2; the disease is central nervous system cancer.